Celldex Announces Initial Positive Results from Phase 1
–Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium– HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—mast cell depletion via stem cell factor … Read more